Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Genfit selloff on data speculation unwarranted, says B. Riley FBR » 12:06
01/23/20
01/23
12:06
01/23/20
12:06
GNFT

Genfit

$19.30 /

-0.87 (-4.31%)

B. Riley FBR analyst…

B. Riley FBR analyst Mayank Mamtani says concerns of a delay in the timeline of Genfit's nonalcoholic steatohepatitis Phase III trial are overblown. Today's share weakness is unwarranted as the readout remains on track for Q1, Mamtani tells investors in a research note. The analyst believes Genfit shares could double if the results show a "placebo-adjusted NASH resolution benefit" of between 15% and 20%. Mamtani keeps a Buy rating on the stock with a $43 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Genfit tells Bloomberg that Resolve-IT trial 'progressing as planned'  12:03
01/23/20
01/23
12:03
01/23/20
12:03
GNFT

Genfit

$19.30 /

-0.87 (-4.31%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Recommendations
Roth says Genfit 'unlocking the power' of non-invasive diagnosis of NASH » 09:10
12/19/19
12/19
09:10
12/19/19
09:10
GNFT

Genfit

$16.76 /

-0.29 (-1.70%)

Roth Capital analyst…

Roth Capital analyst Yasmeen Rahimi said there is an "urgent need" for non-invasive testing in non-alcoholic steatohepatitis, or NASH, and her call with Donna Cryer of the Global Liver Institute, and Dr. Suneil Hosmane, Genfit's EVP and Global Head of Diagnostics, provided a better view into the utility and diagnostic value of the company's NIS4 NIT toolkit, which combines four biomarkers to diagnose fibrosis with high predictability. The analyst, who sees Genfit "unlocking the power of non-invasive NASH diagnosis," keeps a Buy rating and EUR70 price target on the company's shares following her expert call.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Roth Capital healthcare analyst to hold an analyst/industry conference call » 09:55
12/18/19
12/18
09:55
12/18/19
09:55
GNFT

Genfit

$17.05 /

+ (+0.00%)

Healthcare Analyst…

Healthcare Analyst Rahimi, along with Dr. Suneil Hosmane, EVP of Strategic Development at Genfit and Donna Cryer, President and CEO of the Global Liver Institute, address how non-invasive testing is a strong tool to accurately identify patients among the sizable NASH population on an Analyst/Industry conference call to be held on December 18 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Roth Capital healthcare analyst to hold an analyst/industry conference call » 04:55
12/18/19
12/18
04:55
12/18/19
04:55
GNFT

Genfit

$17.05 /

-0.21 (-1.22%)

Healthcare Analyst…

Healthcare Analyst Rahimi, along with Dr. Suneil Hosmane, EVP of Strategic Development at Genfit and Donna Cryer, President and CEO of the Global Liver Institute, address how non-invasive testing is a strong tool to accurately identify patients among the sizable NASH population on an Analyst/Industry conference call to be held on December 18 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Roth Capital healthcare analyst to hold an analyst/industry conference call » 11:25
12/12/19
12/12
11:25
12/12/19
11:25
GNFT

Genfit

$16.82 /

+1.44 (+9.36%)

Healthcare Analyst Rahimi…

Healthcare Analyst Rahimi along with Bart Staels, Co-Founder and Chairman of the Scientific Advisory Board at Genfit, discusses the biology underlying PPARalpha and PPARdelta agonism on an Analyst/Industry conference call to be held on December 12 at 12:30 pm.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Roth Capital healthcare analyst to hold an analyst/industry conference call » 04:55
12/12/19
12/12
04:55
12/12/19
04:55
GNFT

Genfit

$15.38 /

-0.805 (-4.97%)

Healthcare Analyst Rahimi…

Healthcare Analyst Rahimi along with Bart Staels, Co-Founder and Chairman of the Scientific Advisory Board at Genfit, discusses the biology underlying PPARalpha and PPARdelta agonism on an Analyst/Industry conference call to be held on December 12 at 12:30 pm.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Roth Capital healthcare analyst to hold an analyst/industry conference call » 12:20
12/09/19
12/09
12:20
12/09/19
12:20
GNFT

Genfit

$15.60 /

-0.16 (-1.02%)

Healthcare Analyst…

Healthcare Analyst Rahimi, along with Dr. Suneil Hosmane, EVP of Strategic Development at Genfit and Donna Cryer, President and CEO of the Global Liver Institute, address how non-invasive testing is a strong tool to accurately identify patients among the sizable NASH population on an Analyst/Industry conference call to be held on December 18 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Roth Capital healthcare analyst to hold an analyst/industry conference call » 11:52
12/09/19
12/09
11:52
12/09/19
11:52
GNFT

Genfit

$15.60 /

-0.16 (-1.02%)

Healthcare Analyst Rahimi…

Healthcare Analyst Rahimi along with Bart Staels, Co-Founder and Chairman of the Scientific Advisory Board at Genfit, discusses the biology underlying PPARalpha and PPARdelta agonism on an Analyst/Industry conference call to be held on December 12 at 12:30 pm.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Favorable safety a positive for Genfit's elafibranor, says H.C. Wainwright » 14:01
11/26/19
11/26
14:01
11/26/19
14:01
GNFT

Genfit

$15.84 /

+0.53 (+3.46%)

, CBAY

CymaBay

$1.47 /

+0.13 (+9.70%)

, ICPT

Intercept

$100.86 /

+4.62 (+4.80%)

After Genfit (GNFT) this…

After Genfit (GNFT) this morning announced that the Data Safety Monitoring Board issued a positive recommendation for the continuation, without any modifications, of the Resole-It Phase 3 trial evaluating elafibranor in nonalcoholic steatohepatitis, H.C. Wainwright analyst Ed Arce noted this is the seventh such report affirming the favorable safety profile of elafibranor. After CymaBay (CBAY) announced yesterday that it has halted all clinical development of its lead drug seladelpar, Arce also noted that there have been no cases of interface hepatitis seen in all trials to date with elafibranor. "One less competitor only benefits the other players in the space, and the two remaining PPARs, especially elafibranor," added Arce. Commenting further on Intercept's (ICPT) announcement yesterday that the FDA has accepted its NDA for obeticholic acid for accelerated approval for the treatment of fibrosis due to NASH, Arce said he sees "two very differentiated profiles with the first two drugs likely to be approved for NASH," namely Intercept's OCA and Genfit's elafibranor. The analyst, who concludes with the assertion that the "overall efficacy, safety and tolerability profile of elafibranor is hands down superior to that of OCA," keeps a Buy rating and $58 price target on Genfit shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.
友情链接:幸运飞艇官方开奖2020幸运飞艇计划网幸运飞艇走势图幸运飞艇历史开奖结果筛选